
    
      The purpose of this study is to evaluate the bio-equivalence of a single oral administration
      of TAK-536 pediatric formulation (granules) in comparison with a TAK-536 commercial
      formulation (tablet) in healthy adult male participants in an open label, 2-period,
      2-treatment, cross-over design.
    
  